Insider transaction: Bigal Marcelo reduces direct holdings to 11,393 shares in PCRX

Rhea-AI Filing Summary

Pacira BioSciences director Bigal Marcelo reported a sale of 4,912 shares of common stock at $23.67 per share on 08/07/2025, reducing his direct holding to 11,393 shares. The Form 4 discloses no derivative transactions. The filing documents an insider sale and the remaining direct beneficial ownership reported by the director.

Positive

• Disclosure filed via Form 4, meeting Section 16 reporting requirements
• Director retains direct ownership of 11,393 shares after the sale

Negative

• Insider sale of 4,912 shares was reported
• Sale price was $23.67 per share, reducing the director's stake

Insights

Financial Analyst

TL;DR: Director sold 4,912 PCRX shares at $23.67, leaving 11,393 shares; transaction appears routine with limited disclosed context.

The Form 4 shows a single non-derivative sale by Director Bigal Marcelo on 08/07/2025 of 4,912 shares at $23.67, with 11,393 shares held directly after the sale. No derivative positions are reported. The filing provides clear disclosure but lacks context on timing or intent, so material market impact cannot be determined from this form alone.

Corporate Governance Expert

TL;DR: Timely Form 4 disclosure of an insider sale; records show direct ownership remains after the transaction.

The report identifies the reporting person as a Company director and records a sale transaction with subsequent direct beneficial ownership. Table II is empty, indicating no options or other derivatives were acquired or disposed. The form is signed by an attorney-in-fact, showing formal compliance with Section 16 reporting requirements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BIGAL MARCELO

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/07/2025		S		4,912	D	$23.67	11,393	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Pacira BioSciences insider Bigal Marcelo report (PCRX)?

He reported a sale of 4,912 shares of common stock at $23.67 per share on 08/07/2025, leaving 11,393 shares owned directly.

What form was filed to report this insider activity for PCRX?

A Form 4 was filed, which reports changes in beneficial ownership under Section 16.

Were any derivative securities reported in the filing?

No. Table II for derivative securities is empty; only a non-derivative sale is reported in Table I.

What is Bigal Marcelo's relationship to Pacira BioSciences (PCRX)?

The filing lists Bigal Marcelo as a Director of Pacira BioSciences.

Who signed the Form 4 report for this transaction?

The form is signed by Kristen Williams, Attorney-in-Fact on behalf of the reporting person.